Open AccessTransforming growth factor‐beta 1 serum levels in pregnancy and pre‐eclampsia
Author(s) -
Huber Ambros,
Hefler Lukas,
Tempfer Clemens,
Zeisler Harald,
Lebrecht Antje,
Husslein Peter
Publication year - 2002
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.1034/j.1600-0412.2002.810214.x
Subject(s) - pathogenesis , medicine , eclampsia , endocrinology , pregnancy , transforming growth factor , proteinuria , birth weight , preeclampsia , kidney , biology , genetics
Background. Isoforms of transforming growth factor‐beta (TGF‐β1) are thought to be involved in the pathogenesis of pre‐eclampsia. Data with respect to TGF‐β1 are controversial. We examined the correlation between TGF‐β1 serum levels and the occurrence and severity of pre‐eclampsia. Methods. Transforming growth factor‐beta 1 serum levels were measured using a commercially available enzyme‐linked immunosorbent assay in 44 women with pre‐eclampsia and 44 healthy pregnant women. Results were correlated with clinical data. Results. No difference in TGF‐β1 serum levels was assessed between women with pre‐eclampsia and healthy pregnant women. Transforming growth factor‐beta 1 serum levels were not associated with the severity of the disease and were not correlated with clinical maternal (blood pressure, proteinuria) and fetal (5‐min APGAR score, umbilical cord pH values, birth weight) parameters. Conclusions. Our data support the assumption that in contrast to other isoforms, TGF‐β1, as evidenced by serum TGF‐β1 levels, does not seem to be involved in the pathogenesis of pre‐eclampsia.